Phosphate Binders for Managing Hyperphosphatemia

Introduction to Phosphate Binders

Both calcium-based phosphate binders and non-calcium-based phosphate binders, such as sevelamer, are effective in lowering serum phosphorus levels and can be used to manage hyperphosphatemia in patients with chronic kidney disease, as recommended by the American Journal of Kidney Diseases 1, 2

Calcium-based binders, including calcium acetate and calcium carbonate, are effective, widely used, and relatively inexpensive options for lowering serum phosphorus, according to the American Journal of Kidney Diseases 3, 1
Sevelamer, a non-calcium, non-aluminum phosphate binder, effectively reduces serum phosphorus without increasing calcium levels, as noted by the American Journal of Kidney Diseases 2
Lanthanum carbonate, a non-calcium-based binder, has high phosphate binding capacity, as reported by the American Journal of Kidney Diseases 4
Aluminum-based binders may be used only as short-term therapy (maximum 4 weeks) in patients with severe hyperphosphatemia due to toxicity concerns, as stated by the American Journal of Kidney Diseases 5

For most patients, calcium-based phosphate binders, such as calcium acetate or calcium carbonate, are reasonable initial choices due to effectiveness and lower cost, as recommended by the American Journal of Kidney Diseases 1
The total dose of elemental calcium from calcium-based binders should not exceed 1,500 mg/day, and total calcium intake should not exceed 2,000 mg/day, according to the American Journal of Kidney Diseases 1, 5

In patients with calciphylaxis, non-calcium containing binders are preferred to limit exposure to excess calcium and phosphate, as suggested by Praxis Medical Insights 6
Sevelamer has proven efficacy and safety in pediatric patients with chronic kidney disease, particularly when hypercalcemia is a concern, as reported by the American Journal of Kidney Diseases 4

Serum phosphorus levels should be monitored monthly following initiation of phosphate binder therapy, as recommended by the American Journal of Kidney Diseases 1
Serum calcium levels should be regularly assessed to detect hypercalcemia, especially with calcium-based binders, according to the American Journal of Kidney Diseases 2
PTH levels should be monitored to avoid oversuppression when using calcium-based binders, as noted by the American Journal of Kidney Diseases 3
Patients on long-term calcium-based binder therapy should be assessed for signs of vascular calcification, as reported by the American Journal of Kidney Diseases and Annals of Internal Medicine 3, 7

Phosphate binders should not be initiated in patients with normal phosphate levels, as this may not be beneficial and could potentially be harmful, as stated by Annals of Internal Medicine 7, 8, 9
Aluminum-based binders should only be used short-term (≤4 weeks) due to risk of toxicity, as warned by the American Journal of Kidney Diseases 5

The National Kidney Foundation recommends that phosphate binders, including calcium-based agents (calcium acetate, calcium carbonate), calcium-free binders (sevelamer, lanthanum carbonate, sucroferric oxyhydroxide), and magnesium salts, be used to reduce serum phosphate levels in patients with chronic kidney disease 10

The American College of Physicians suggests that calcium-based phosphate binders can be used as initial therapy for patients with stages 3-4 chronic kidney disease, with the goal of maintaining serum phosphate levels between 2.7-4.6 mg/dL 10
For patients with stage 5 chronic kidney disease on dialysis, the National Kidney Foundation recommends initiating phosphate binders when serum phosphate levels exceed 5.5 mg/dL, with a goal of maintaining levels between 3.5-5.5 mg/dL 10

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend dietary phosphate restriction as the first step in managing hyperphosphatemia, with a daily intake of 800-1000 mg, adjusted for protein dietary needs 10, 11
Patients should be educated on the bioavailability of phosphate: organic phosphate from animal sources (40-60% absorbed) versus phosphate from plant sources (20-50% absorbed) versus inorganic phosphate from food additives (highly absorbable) 12, 13

Calcium-free phosphate binders (sevelamer, lanthanum, sucroferric oxyhydroxide) are preferred in patients with hypercalcemia (corrected serum calcium >10.2 mg/dL) or parathyroid hormone (PTH) levels <150 pg/mL in two consecutive measurements 10
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize that not all phosphate binders are interchangeable, and clinical trial evidence has not definitively demonstrated the superiority of one class of binders over another with respect to clinical outcomes such as mortality 12, 13